ResMed Inc. (NYSE:RMD) Stock Has Consensus Price Target of $243.23

Posted by Geri Gentry on Oct 28th, 2026

Shares of ResMed Inc. (NYSE:RMD – Get Free Report) have been assigned an average recommendation of “Hold” from the sixteen analysts that are covering the company, MarketBeat reports. Nine research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $243.23.

A number of equities analysts have recently issued reports on RMD shares. UBS Group reaffirmed a “buy” rating and set a $300.00 price target on shares of ResMed in a research report on Tuesday, July 21st. Mizuho set a $240.00 target price on shares of ResMed in a research note on Tuesday, October 13th. KeyCorp upped their price objective on shares of ResMed from $255.00 to $267.00 and gave the stock an “overweight” rating in a research report on Monday, August 31st. Piper Sandler decreased their price objective on ResMed from $233.00 to $225.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of ResMed in a report on Wednesday, July 1st.

Read Our Latest Report on ResMed

ResMed Stock Down 1.1%

Shares of NYSE:RMD opened at $250.52 on Wednesday. The firm’s 50 day simple moving average is $230.81 and its 200-day simple moving average is $225.58. ResMed has a one year low of $180.26 and a one year high of $277.67.

ResMed (NYSE:RMD – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $2.95 EPS for the quarter, beating the consensus estimate of $2.89 by $0.06. The firm had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.46 billion. The business’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.55 EPS. As a group, equities analysts expect that ResMed will post 12.11 earnings per share for the current year.

ResMed Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 24th. Shareholders of record on Thursday, August 20th were issued a dividend of $0.66 per share. This is a boost from ResMed’s previous quarterly dividend of $0.60. The ex-dividend date was Thursday, August 20th. This represents a $2.64 annualized dividend and a yield of 1.1%.

Insider Transactions at ResMed

In related news, General Counsel Michael Rider sold 400 shares of the company’s stock in a transaction that occurred on Friday, October 23rd. The stock was sold at an average price of $255.00, for a total value of $102,000.00. Following the completion of the transaction, the general counsel directly owned 12,318 shares of the company’s stock, valued at $3,141,090. This represents a 3.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter Farrell sold 8,000 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $225.00, for a total transaction of $1,800,000.00. Following the completion of the transaction, the director owned 52,773 shares of the company’s stock, valued at $11,873,925. This represents a 13.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 24,343 shares of company stock valued at $5,396,098. 0.58% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ResMed

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bell Investment Advisors Inc acquired a new position in shares of ResMed during the 2nd quarter worth approximately $26,000. Trust Co. of Vermont acquired a new position in ResMed during the second quarter valued at approximately $39,000. Kelleher Financial Advisors acquired a new position in shares of ResMed during the 2nd quarter valued at $47,000. Ballast Advisors LLC purchased a new position in shares of ResMed in the first quarter valued at $84,000. Finally, Harbor Investment Advisory LLC grew its stake in shares of ResMed by 82.6% during the second quarter. Harbor Investment Advisory LLC now owns 409 shares of the medical equipment provider’s stock valued at $80,000 after acquiring an additional 185 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.

About ResMed

(Get Free Report)

ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.

ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.